Skip to content

Released Aug 8, 2017, after the close

10-Q filed Aug 8, 2017, 39 days after period end · 0001232524-17-000134

Q2 2017 · 10-Q
Revenue$394.39M+3.5% vs Q2 2016+4.9% vs Q1 2017
Net Income$105.60M−7.8% vs Q2 2016+22.1% vs Q1 2017
EPS Diluted$1.72−7.0% vs Q2 2016+22.0% vs Q1 2017
Gross Profit$360,983,000+1.6%
Operating Income$165,043,000−2.2%
Operating Cash Flowderived$135,091,000+6.4%
Free Cash Flowderived$126,940,000+2.8%
Margins · derived
Gross margin91.5%−1.6 pt vs Q2 2016
Operating margin41.8%−2.4 pt vs Q2 2016
Net margin26.8%−3.3 pt vs Q2 2016

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2017Q2 2016Q2 2015Q2 2014
Revenue$394.39M$381.16M$333.75M$291.23M
Net Income$105.60M$114.50M$88.11M$43.66M
EPS Diluted$1.72$1.85$1.40$0.70

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR